Praxis Precision Medicines To Participate In Upcoming Fireside Chat

2025-08-29 08:01:28

(MENAFN- GlobeNewsWire - Nasdaq) BOSTON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Ritu Baral, Biotechnology Analyst, TD Cowen on September 2, 2025 at 10:00amEST to discuss content shared by Praxis at the 36^th International Epilepsy Consortium (IEC).

The registration link for the fireside chat can be found here .

The overview of Praxis' posters and presentation at the IEC event can be found here .

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, CerebrumTM, and antisense oligonucleotide (ASO) platform, SolidusTM, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit and follow us on Facebook , Instagram , LinkedIn and Twitter/X .

CONTACT: Investor Contact: Praxis Precision Medicines ... 857-702-9452 Media Contact: Dan Ferry Life Science Advisors ... 617-430-7576

MENAFN29082025004107003653ID1109993040

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.